Fosgemcitabine palabenamide
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Fosgemcitabine palabenamide
- Molecular weight
- 580.48
- Structure (SMILES)
- C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1
- acelarin
- Acelarin
- bio 1031
- BIO-1031
- cpf 31
- CPF-31
- cpf31
- CPF31
- fosgemcitabine palabenamide
- Fosgemcitabine palabenamide
- fosgemcitabine palabenamide p rs
- Fosgemcitabine palabenamide, p(rs)-
- gemictabine protide
- Gemictabine protide
- nuc 1031
- nuc 1031 500 mg
- nuc 1031 750mg
- nuc 1031 and carboplatin
- nuc 1031 s
- Nuc-1031
- NUC-1031
- NUC-1031 500 mg
- NUC-1031 750mg
- NUC-1031, (S)-
- CAS registry numbers
- 840506-29-8
- ChEMBL ID
- CHEMBL3126004
- InChIKey
- NHTKGYOMICWFQZ-KKQYNPQSSA-N
- PubChem compound IDs
- 11169170
- FDA ingredient codes (UNII)
- XCL1K2T28K
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -citabine; fos-
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009534
- Subject identifier
- D001661
- Condition
- Biliary Tract Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0003060
- Subject identifier
- D001661
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0009534
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003210
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004868
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005192
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005411
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0017590
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0019087
- Highest recorded phase
- 1
- NCT01621854
- NCT03146663
- NCT03610100
- NCT04163900
- Hydrogen bond acceptors
- 11
- Hydrogen bond donors
- 3
- Polar surface area
- 164.23
- Calculated partition coefficient (ALogP)
- 2.64
- Calculated partition coefficient (XLogP)
- 1.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 40
- Molecular formula
- C25H27F2N4O8P
- Monoisotopic mass
- 580.15345715
- Natural product
- No
- Recorded assays
- 129
- Active assays
- 37
Active assay types
- Confirmatory
Related records
Trials (11)
- ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
- ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
- Acelarin First Line Randomised Pancreatic Study
- Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
- Neoadjuvant Treatment in Resectable Pancreatic Cancer
- NUC-1031 in Patients With Advanced Solid Tumours
- NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
- Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
- Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
In development for (11)
- Alzheimer disease Phase 1
- Biliary tract cancer Phase 3
- Biliary tract disorder Phase 3
- Cancer Phase 1
- Carcinoma of the ampulla of vater Phase 3
- Cholangiocarcinoma Phase 1
- Exocrine pancreatic carcinoma Phase 2
- Gallbladder cancer Phase 3
- Intrahepatic cholangiocarcinoma Phase 3
- Neoplasm Phase 1
- Ovarian cancer Phase 2